Precision Biosciences (DTIL) Operating Expenses (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Operating Expenses data on file, last reported at $19.9 million in Q1 2026.

• On a quarterly basis, Operating Expenses fell 10.06% year-over-year to $19.9 million in Q1 2026; TTM through Mar 2026 was $84.2 million, a 11.6% decrease from a year earlier, with the FY2025 full-year figure at $86.4 million, down 8.9% from the prior year.
• Operating Expenses for Q1 2026 stood at $19.9 million, down from $21.7 million in the prior quarter.
• Over the last five years, Operating Expenses for DTIL reached as high as $33.4 million in Q2 2022 and fell as low as $19.9 million in Q1 2026.
• Historically, Operating Expenses has averaged $23.7 million across 5 years, with a median of $22.1 million in 2023.
• Across the five-year window, Operating Expenses tumbled 38.73% in 2022 and grew 16.22% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $22.7 million in 2022, then decreased by 3.43% to $21.9 million in 2023, then climbed by 16.22% to $25.5 million in 2024, then retreated by 14.86% to $21.7 million in 2025, then declined by 8.22% to $19.9 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $19.9 million in Q1 2026, $21.7 million in Q4 2025, and $20.7 million in Q3 2025.